Safety of difelikefalin for itching in teens on dialysis
Part of Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a drug called difelikefalin to see if it safely reduces moderate-to-severe itching in teenagers who are on hemodialysis. Itching is common in kidney disease, and this study aims to find a new treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 17 years old
- You have been on hemodialysis 3 times a week for at least 12 weeks
- You have had moderate-to-severe itching for at least 4 days in the past week
- You weigh at least 44 pounds (20 kg)
- Your itching is not caused by other skin conditions like eczema or hives
- You are not planning to get a kidney transplant during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether dupilumab injections can reduce severe itching that has no clear cause. It also checks how safe the medicine is over the study period.
This study looks at itching caused by drug-induced liver injury. Researchers want to understand who gets itchy and how bad it is, which could help improve care for people with this condition.
This trial tests a drug called difelikefalin to see if it can reduce severe itching in people on hemodialysis for chronic kidney disease. If you have troublesome itching despite dialysis, this treatment might help relieve it.
This trial tests if a medication called nalfurafine hydrochloride (taken as a tablet that melts in your mouth) can help reduce moderate to severe itching in people receiving peritoneal dialysis for chronic kidney disease.
This study tests a new oral medication, nalfurafine hydrochloride, to see if it helps reduce itching in people on dialysis. It might offer a new option for those whose current itch treatments haven't been effective.
This study tests a medication called nalfurafine to see if it can reduce severe itching (pruritus) that often comes with advanced kidney disease in people on dialysis. If you have moderate to severe itching and have been on dialysis twice a week for more than 6 months, this trial may offer a potential new treatment option.
Hear when a new Pruritus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.